ASX Announcements

Oct 2018
Oct 17th, 2018
Starpharma Investor Presentation for Citi Conference
Oct 8th, 2018
Ceasing to be a substantial holder
Oct 5th, 2018
Change in Director's Interest Notice - J Fairley
Oct 5th, 2018
Appendix 3B
Oct 2nd, 2018
Notification of AGM date

Sep 2018
Sep 14th, 2018
Change in substantial holding
Sep 5th, 2018
DEP® irinotecan outperforms in pancreatic cancer model

Aug 2018
Aug 31st, 2018
AstraZeneca’s DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination
Aug 21st, 2018
Appendix 4G - Corporate Governance Statement
Aug 21st, 2018
Annual report and full year financial results

Jul 2018
Jul 17th, 2018
Quarterly Cashflow Report
Jul 9th, 2018
VivaGel® BV NDA advances to next stage of FDA review

Jun 2018
Jun 27th, 2018
Starpharma licenses VivaGel® BV to Mundipharma for Europe
Jun 6th, 2018
Change in substantial holding

May 2018
May 17th, 2018
Change in Director's Interest Notice - R Thomas
May 3rd, 2018
Mundipharma licenses Starpharma’s VivaGel® BV

Apr 2018
Apr 30th, 2018
Starpharma completes US New Drug Application for VivaGel BV
Apr 30th, 2018
Quarterly Cashflow Report
Apr 11th, 2018
Starpharma to present at OTCQX Virtual Investor Conference

Mar 2018
Mar 21st, 2018
Change in Director's Interest Notice - J Fairley
Mar 20th, 2018
Change in Director's Interest Notice - R Thomas
Mar 20th, 2018
Appendix 3B
Mar 15th, 2018
Change in Director's Interest Notice - R Thomas
Mar 12th, 2018
Change in Director's Interest Notice - P Turvey
Mar 12th, 2018
Change in Director's Interest Notice - J Fairley
Mar 5th, 2018
Change in Director's Interest Notice - R Thomas

Feb 2018
Feb 26th, 2018
Interim Report and Half-Yearly Financial Results
Feb 22nd, 2018
Starpharma receives $3.7M R&D tax incentive refund
Feb 19th, 2018
Shareholder Update February 2018

Jan 2018
Jan 31st, 2018
Starpharma to commence DEP® cabazitaxel phase 1/2 trial
Jan 29th, 2018
Appendix 3B
Jan 25th, 2018
Appendix 4C - Quarterly Cashflow Report